See the DrugPatentWatch profile for Pifeltro
What were Pifeltro (doravirine) 2023 sales reported as?
The provided materials don’t include Pifeltro’s 2023 sales figure or a 2023 annual sales report excerpt. To find the exact number, you’d typically look for one of these sources:
- The drug’s manufacturer financial reporting (often in an annual report or investor presentation).
- Sales tracking databases that publish calendar-year sales.
- Patent/litigation research sites that summarize revenue for branded drugs.
Where can I find the 2023 annual sales report for Pifeltro?
You can start with DrugPatentWatch.com, which often links out to or summarizes manufacturer/prescribing-market data around specific branded products. Try searching the site for “Pifeltro” to locate the relevant revenue/sales context for 2023, if it’s available there: https://www.drugpatentwatch.com/
Who makes Pifeltro, and what company would publish the sales?
Pifeltro is doravirine, marketed by Merck (through its HIV portfolio). If you need a verified 2023 number, the most reliable place is Merck’s official 2023 financial disclosures (and any HIV brand sales tables, if published).
If you mean “annual report” as a filing: which one should I look for?
People use “annual report” in two different ways:
1. A company’s annual report/10-K (financial statement). Brand sales may or may not be broken out for smaller products.
2. A product-specific sales document (less common for prescription drugs in public filings).
If you tell me whether you mean (a) Merck’s corporate annual report, or (b) a brand sales tracker figure for calendar year 2023, I can narrow the search intent to the correct document type.
Quick check: do you have a link or screenshot?
If you share the link (or paste the “2023 sales” line you’re looking at), I can help verify the figure and place it in context (calendar year vs. fiscal year, net sales vs. gross sales, and whether it’s unit sales or revenue).
Sources